Navigation Links
Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009
Date:4/15/2009

tional anti-TNF market growth trends remain strong, and HUMIRA maintains a market-leading position in many of the international markets. Synthroid, Lupron and Norvir also contributed to the international growth, as well as a number of other established products.

As expected, U.S. pharmaceutical sales reflected the first quarter impact of generic competition for both forms of Depakote; Depakote DR and Depakote ER. This resulted in a $230 million decline in Depakote sales in the first quarter, reducing U.S. pharmaceutical sales growth by more than 13 percentage points. Total U.S. pharmaceutical sales were approximately $150 million below our expectations for the quarter, due to somewhat slower-than-expected market growth in certain segments, including self-injectable anti-TNF's, and a related one-time reduction in customer purchases. HUMIRA accounted for somewhat more than half of the $150 million. In the U.S., HUMIRA continues to grow significantly faster than the market and continues to gain market share. Total U.S. HUMIRA prescriptions increased approximately 18 percent in the first quarter compared to the prior year, indicating strong underlying demand.

For the full-year 2009, Abbott is forecasting global HUMIRA operational sales growth of 25 to 30 percent, excluding the negative impact of exchange, and global HUMIRA reported sales growth of 15 to 20 percent, including exchange. This includes forecasted international reported sales growth of more than 20 percent, including an expected negative impact from exchange approaching 20 percent, and U.S. HUMIRA growth in the low double-digits. Our updated full-year HUMIRA forecast captures current market dynamics as well as negative exchange rate trends.

Also in the quarter, we launched TRILIPIX, our next generation fenofibric acid. Uptake has been driven by the safety and efficacy data and labeled indication for use of TRILIPIX in combination with statins. Also, we
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
2. Abbott Hosts Conference Call for First-Quarter Earnings
3. Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter
4. Abbott to Present at Cowen Annual Health Care Conference
5. Abbott Announces Required Offer to Repurchase Convertible Senior Subordinated Notes of Its AMO Subsidiary
6. Abbott Completes Acquisition of Advanced Medical Optics
7. Abbott Opens New Pediatric Nutrition Manufacturing Facility in Singapore
8. Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics
9. Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
10. Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
11. Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Concorde Career College North Hollywood ... the 2014 Excellence in Community Service Award from ... (ACCSC). , Every year, the Accrediting Commission of ... make outstanding contributions in their local community through ... scope and impact of the community service and ...
(Date:9/2/2014)... ROCHESTER, Minn. How well patients recover from ... their medical conditions and the operations themselves. Family ... risk of surgical complications, a Mayo Clinic study ... operation may reduce patients, stress, speed their recoveries ... The study specifically looked at colon cancer patients, ...
(Date:9/2/2014)... in their work care for patients who are dying. ... that many nurses in training feel unprepared and anxious ... end-of-life care. , Scientists from the Sahlgrenska Academy have ... the University of Skvde and the Ersta Skndal University ... for dying patients, their ideas about how to support ...
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... September 02, 2014 The performance of ... over the past five years. Industry revenue is estimated ... over the five years through 2014-15, following stabilised growth ... increasing external competition from alternate forms of gambling. Horse ... online gambling platforms have all become increasingly popular over ...
Breaking Medicine News(10 mins):Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:Many nurses unprepared to meet dying patients 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Shengtai Pharmaceutical, Inc. (OTC,Bulletin Board: SGTI) ("Shengtai Pharmaceutical" ... high-quality, pharmaceutical grade,glucose products in China, today reported ... 2007., Second Quarter of Fiscal 2008 ... $25.0 million -- Gross profit rose 91% ...
... treatments for the disease, study suggests , , THURSDAY, Feb. 14 ... cells into mice with hemophilia enables the animals to produce ... hemophilia. , The breakthrough finding may lead the way to ... of the disease, researchers believe. , "We were able to ...
... /PRNewswire-FirstCall/ - NUCRYST,Pharmaceuticals Corp. (NASDAQ: NCST ; TSX: ... 2007. Net loss narrowed to $4.0 million, or 22,cents ... to a net loss,of $10.5 million, or 58 cents ... year. The lower net loss for 2007 is primarily ...
... MONTREAL, Feb. 14 /PRNewswire-FirstCall/ - CryoCath(R) Technologies,Inc., the ... announced financial results for the first quarter, ended,December 31, ... Highlights: - EP Revenue for Q1 2008 ... over Q1 2007. All regions around ...
... people,through the U.S. Agency for International Development (USAID), ... Tajikistan after extreme winter weather,and an energy crisis ... This,funding will help provide fuel, heaters, clothing, household ... USAID partners Save the Children,CARE, and Mercy Corps., ...
... 14 Today, Lung Cancer,Alliance announced that for the ... called for a screening program for veterans at high,risk ... USN, (Ret.), chairman of LCA,s Board of,Directors said today, ... these organizations for speaking out about the number one,cancer ...
Cached Medicine News:Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 12Health News:Transplanted Liver Lining Cells May Cure Hemophilia 2Health News:NUCRYST Pharmaceuticals announces year-end results 2Health News:NUCRYST Pharmaceuticals announces year-end results 3Health News:NUCRYST Pharmaceuticals announces year-end results 4Health News:NUCRYST Pharmaceuticals announces year-end results 5Health News:NUCRYST Pharmaceuticals announces year-end results 6Health News:NUCRYST Pharmaceuticals announces year-end results 7Health News:NUCRYST Pharmaceuticals announces year-end results 8Health News:NUCRYST Pharmaceuticals announces year-end results 9Health News:NUCRYST Pharmaceuticals announces year-end results 10Health News:NUCRYST Pharmaceuticals announces year-end results 11Health News:NUCRYST Pharmaceuticals announces year-end results 12Health News:CryoCath Announces Fiscal 2008 First Quarter Results 2Health News:CryoCath Announces Fiscal 2008 First Quarter Results 3Health News:CryoCath Announces Fiscal 2008 First Quarter Results 4Health News:CryoCath Announces Fiscal 2008 First Quarter Results 5Health News:CryoCath Announces Fiscal 2008 First Quarter Results 6Health News:CryoCath Announces Fiscal 2008 First Quarter Results 7Health News:CryoCath Announces Fiscal 2008 First Quarter Results 8Health News:CryoCath Announces Fiscal 2008 First Quarter Results 9Health News:CryoCath Announces Fiscal 2008 First Quarter Results 10Health News:CryoCath Announces Fiscal 2008 First Quarter Results 11Health News:Veterans Organizations Call for Lung Cancer Screening 2Health News:Veterans Organizations Call for Lung Cancer Screening 3
(Date:9/2/2014)... Sept. 2, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the Morgan ... at 10:20 a.m. ET. The conference will be held ... New York City . About Abaxis ...
(Date:9/2/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today announced ... will present at the Morgan Stanley Global Healthcare Conference in ... York on Tuesday, September 9, 2014 at 12:20 ... listen to the live audio webcast of the presentation on ... An archive of the presentation will be available for replay ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014  Arena ... that the US Food and Drug Administration (FDA) has ... of pulmonary arterial hypertension. "The FDA ... clinical data submissions from sponsors to identify and designate ... help advance the evaluation and development of such products," ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... ARLINGTON HEIGHTS, Ill., Sept. 12 Even as,many ... available today,we are stopped by our rear reflection and ... study published in the October issue of Plastic and,Reconstructive ... Plastic Surgeons (ASPS), reveals a new back lift procedure ...
... Ala., Sept. 11 - Southern,Research Institute and ... from a study testing Naltrexone-derived,pyridomorphinan (SoRI-9409) will ... of,the journal Biological Psychiatry. The publication is ... suggests that a new compound that,causes selective ...
Cached Medicine Technology:Say 'Goodbye' to Back Fat Rolls 2Novel Compound Shows Promise for Treatment of Alcoholism 2Novel Compound Shows Promise for Treatment of Alcoholism 3Novel Compound Shows Promise for Treatment of Alcoholism 4
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: